🚀
Enjoy a 7-Day Free Trial Thru May 05, 2024!
✨
Sign Up
Login
Free Sign-up
Login
7-Day Free Trial
Home
Homepage
Membership Levels
About Us
General Discussion
Complete Stock List
The book
Membership Data Coverage
Founder's Message
Free Trial
Referral Program
Partner Program
GuruFocus Podcast
Screeners
GuruFocus Screeners
All-In-One Screener
Ben Graham Lost Formula
Canadian Faster Growers
CEO Buys
CEO Buys after Price Drop > 20%
Dividend Kings 2023
Dividend Aristocrats 2023
Dividend Growth Portfolio
Dividend Income Portfolio
Fast Growers
Good Companies
Hedge Fund Guru Top 10 Aggregated
High Quality
High Quality Low Capex w ROE ROC min
High Quality & Low Capex
High Yield Insider Buys
Historical High Dividend Yields
International Gurus' Top Holdings
James Montier Short Screen
Margin Decliners
Mega Caps
Peter Lynch & Warren Buffett
Peter Lynch Growth w Lower Valuation
Peter Lynch S&L Traded Below Book
PFCF Screener
Piotroski Score Screener
Predictable Growth Companies
Profitable predictable margin expanders
Stocks Sold w less Cash
The Stalwarts
My Screeners
Create My Screener
Value Screens
Stock Ideas
All-In-One Screener
S&P 500 Map
S&P 500 Bubble
S&P 500 Aggregate
Buffett-Munger Screener
Industry Overview
Undervalued Predictable
Benjamin Graham Net-Net
52-week/3Y/5Y Lows
52-week/3Y/5Y Highs
Magic Formula(Greenblatt)
Dividend Stocks
Peter Lynch Screen
S&P500 Grid
Predictable Companies
Spin Off List
Merger and Acquisition List
Historical Low P/B List
Historical Low P/S List
High Short Interest
Upcoming Special Dividends
Delisted Stocks
Model Portfolios
Performances Overview
Most Broadly Held Portfolio
Most Weighted Portfolio
Buffett-Munger Top 25
GF Score <= 100 Top 25
Top 25 Undervalued Predictable
Top 25 52-week Low Predictable
Top 25 Historical Low P/S
Stock Comparison
Airline Stocks
Artificial Intelligence Stocks
Bank Stocks
Biotech Stocks
Blockchain Stocks
Chinese Stocks
Dividend Stocks
EV Stocks
Growth Stocks
Oil Stocks
Value Stocks
Virtual Reality Stocks
Compare More Stocks…
Gurus
Guru Trades
Latest Guru Picks
Real Time Picks
Guru Portfolio
Score Board
Mutual Funds
Top 10 Holdings
Sector Picks
International Picks
Aggregated Portfolio
Consensus Picks
Guru Bargains
Hot Picks
Download Guru Portfolios
Industry Trends
Geographic Trend
ETFs
Options Holdings
European Shorting
Guru Lists
Complete Guru List
Warren Buffett
Bill Gates
Mohnish Pabrai
Carl Icahn
George Soros
David Tepper
Seth Klarman
Bill Ackman
Joel Greenblatt
Charlie Munger
Michael Price
Julian Robertson
Chuck Akre
David Einhorn
Tom Gayner
My Guru Lists
Insiders
Insider Trading Tracker
Real-Time Insider Picks
CEO Buys/Sells
CFO Buys/Sells
Insider Trends
Insider Cluster
Guru + Insider Double Buys
Triple Buys/Sells
Chinese Insider
German Insider
Complete Insider List
Politician Trading Tracker
Real-Time Politician Picks
Complete Politician List
Nancy Pelosi
Mitch Mcconnell
Tommy Tuberville
Josh Gottheimer
Kevin Hern
Thomas R. Carper
Susie Lee
Lois Frankel
Market
US Market Valuation
Buffett Indicator
U.S. Treasury Yield Curve
U.S. Inflation Rate
Presidential Cycle and Stock Market
Shiller P/E
Shiller P/E by Sectors
GF Value for S&P 500 Index
Fed Net Liquidity
Buffett Assets Allocation
Latest IPOs
Global Market Valuation
Global Market Overview
USA
China
Japan
India
Canada
UK
France
Germany
Brazil
Australia
More...
Economic Indicators
Economic Indicators Overview
The Dow Jones Industrial Average (DJIA)
SP 500 Index
Nasdaq Composite Index
Gross Domestic Product (GDP)
Shiller PE
Ratio of Wilshire 5000 over GNP
Civilian Unemployment Rate
Russell 2000 Index
CBOE Volatility Index (VIX)
Total Nonfarm Payrolls: All Employees
More...
Sector & Industry Performance
Global Industry Overview
USA
Asia
Europe
Canada
UK/Ireland
Oceania
Latin America
Africa
India/Pakistan
Articles
Articles
Editors' Picks
Stock Market News
Q&A with Gurus
Guru Stock Picks
Insider Transaction
Earning Reports
CEO Shareholder Letters
Podcast
Earnings Call Transcripts
Software Stock News
Biotechnology Stock News
Hardware Stock News
Banks Stock News
Metals & Mining Stock News
Drug Manufacturers Stock News
All Articles
Submit Articles
Submit Article Online
Contributor Guidelines
Tools
Model Portfolios
All-In-One Screener
Data Batch Download
Guru Portfolio Download
Insider Data Download
Excel Add-In
Google Sheets Add-On
API
Manual of Stocks
DCF Calculator
WACC Calculator
Interactive Chart
Maps
Fund Letters Archive
Stock Comparison Table
Mobile App
Discussion Board
GuruGPT
Financial Calendar
Embed Widgets
Stock Market Holidays
Discussion
Discussion Board
GuruFocus Discord
ETF
Data
Pricing
Tutorials
Tutorials
Financial Glossary
FAQ
Change Log
Contact Us
Support
Chat Support
Create a ticket
Book Demo
User Engagement Meeting
469-248-6885
Status
Take Survey
Ask the community in Discord
Subscribe
Free Trial
Group Subscription
Refer a Friend and Earn One Month of Free Membership
GURUFOCUS.COM
STOCK LIST
Healthcare
Biotechnology
Oncotelic Therapeutics Inc (OTCPK:OTLC)
News
Oncotelic Therapeutics Inc
OTCPK
:OTLC (USA) Â
$ 0.04
+0.0012 (+2.94%)
10:08 PM EST
On watch
P/E:
At Loss
P/B:
1.40
Market Cap:
$ 16.79M
Enterprise V:
$ 29.19M
Volume:
22.30K
Avg Vol (2M):
71.75K
Warning! GuruFocus detected 4 Severe warning signs with OTLC.
Try a 7-Day Free Trial
to check it out.
Volume:
22.30K
Market Cap $:
16.79M
PE Ratio:
At Loss
Avg Vol (2M):
71.75K
Enterprise Value $:
29.19M
PB Ratio:
1.40
Alerts
Website
SEC Filings
Stock PDF
Dataset
Financial Download
Manual of Stocks™
Compare
0
Summary
30-Y Financials
Estimates
DCF
Dividend
Guru Trades
Insider
Interactive Chart
Filings
Transcripts
News
Compare
Stock PDF
Ownership
Operating
Checklist
Vote
Definitions
Oncotelic Therapeutics Inc (OTCPK:OTLC) Stock News, Headlines & Updates
Oncotelic Therapeutics Inc Stock News from GuruFocus
Total 126
1
2
3
4
Aug 25, 2023
Oncotelic Therapeutics, Inc. Awarded Top Cancer Immunotherapy Solutions Provider 2023
Marketwired
•
6:00am
Aug 23, 2023
Sapu BioScience and Cromos Pharma initiating P201 -- A Registrational trial for OT-101 in Pancreatic Cancer
Marketwired
•
7:00am
Jan 25, 2023
Oncotelic Initiates Clinical Trials Evaluating OT-101 against Metastatic Pancreatic Cancer
Stock market mentor
•
7:00am
Dec 28, 2022
Oncotelic Issues Year End Message to Shareholders
Tiesvg
•
7:00am
Dec 19, 2022
Oncotelic Presents Clinical Data of Confirming TGF-?2 as the appropriate target for gliomas at JCA-AACR Meeting 2022
Value_Insider
•
7:00am
Nov 30, 2022
Oncotelic Publishes SNO 27th Annual Meeting Presentation Materials
Value_Insider
•
7:00am
Aug 22, 2022
ONCOTELIC REPORTS Q2 2022 COMPARED TO Q2 2021 FINANCIAL RESULTS
PurpleRose
•
9:00am
Aug 17, 2022
Oncotelic Participating at Biotechgate Digital Partnering
PurpleRose
•
7:00am
Jul 15, 2022
Oncotelic Provides Update on OT-101 at the 2022 BIO International Convention
PurpleRose
•
7:29am
Jul 12, 2022
ONCOTELIC PROVIDES Q1 2022 FINANCIAL RESULTS COMPARED TO Q1 2021, PRODUCT DEVELOPMENT INITIATIVES AND CORPORATE UPDATE
PurpleRose
•
11:16am
Oncotelic Announces Presentation of P001- OT-101 Phase 1/2 Trial in Pancreatic Cancer
PurpleRose
•
6:40am
Jul 05, 2022
Oncotelic Provides Update on OT-101 at the 2022 BIO International Convention
GuruFocusNews
•
7:25am
Jul 04, 2022
Oncotelic Therapeutics Receives FDA Clearance for Phase 2 Clinical Trial of OT-101/Pembroluzimab Combination for Mesothelioma (M201)
GuruFocusNews
•
7:15am
Jul 02, 2022
ONCOTELIC PROVIDES Q1 2022 FINANCIAL RESULTS COMPARED TO Q1 2021, PRODUCT DEVELOPMENT INITIATIVES AND CORPORATE UPDATE
GuruFocusNews
•
11:15am
Jun 25, 2022
Oncotelic Provides Update on OT-101 at the 2022 BIO International Convention
GuruFocusNews
•
7:24am
Jun 22, 2022
ONCOTELIC PROVIDES Q1 2022 FINANCIAL RESULTS COMPARED TO Q1 2021, PRODUCT DEVELOPMENT INITIATIVES AND CORPORATE UPDATE
GuruFocusNews
•
11:13am
Jun 15, 2022
Oncotelic Provides Update on OT-101 at the 2022 BIO International Convention
GuruFocusNews
•
6:23am
Jun 14, 2022
Oncotelic Therapeutics Receives FDA Clearance for Phase 2 Clinical Trial of OT-101/Pembroluzimab Combination for Mesothelioma (M201)
GuruFocusNews
•
7:13am
Jun 12, 2022
ONCOTELIC PROVIDES Q1 2022 FINANCIAL RESULTS COMPARED TO Q1 2021, PRODUCT DEVELOPMENT INITIATIVES AND CORPORATE UPDATE
GuruFocusNews
•
11:11am
Jun 07, 2022
Oncotelic Announces Pipeline Presentation and IPO Update of Sapu Therapeutics at the 2022 BIO International Convention
GuruFocusNews
•
7:09am
Jun 04, 2022
Oncotelic Therapeutics Receives FDA Clearance for Phase 2 Clinical Trial of OT-101/Pembroluzimab Combination for Mesothelioma (M201)
GuruFocusNews
•
7:11am
Jun 02, 2022
ONCOTELIC PROVIDES Q1 2022 FINANCIAL RESULTS COMPARED TO Q1 2021, PRODUCT DEVELOPMENT INITIATIVES AND CORPORATE UPDATE
GuruFocusNews
•
11:11am
May 25, 2022
Oncotelic Therapeutics Receives FDA Clearance for Phase 2 Clinical Trial of OT-101/Pembroluzimab Combination for Mesothelioma (M201)
GuruFocusNews
•
6:13am
May 23, 2022
ONCOTELIC PROVIDES Q1 2022 FINANCIAL RESULTS COMPARED TO Q1 2021, PRODUCT DEVELOPMENT INITIATIVES AND CORPORATE UPDATE
GuruFocusNews
•
11:10am
May 18, 2022
Oncotelic Announces Pipeline Presentation and IPO Update of Sapu Therapeutics at the 2022 BIO International Convention
GuruFocusNews
•
7:08am
May 11, 2022
ONCOTELIC ANNOUNCES US PATENT GRANT FOR CA4P AND OXI4503 COMBINATION WITH CHECKPOINT INHIBITORS
GuruFocusNews
•
6:15am
May 04, 2022
Oncotelic Appoints Seymour Fein M.D. as Chief Regulatory Officer
GuruFocusNews
•
6:01am
May 03, 2022
Oncotelic Appoints Fatih Uckun, M.D., Ph.D., as Chief Medical Officer
GuruFocusNews
•
6:00am
Apr 18, 2022
ONCOTELIC PROVIDES YE 2021 FINANCIAL RESULTS COMPARED TO YE 2020, PRODUCT DEVELOPMET INITIATIVES AND CORPORATE UPDATE
GuruFocusNews
•
6:00am
Apr 07, 2022
Letter to Oncotelic Shareholders on the Recently Completed Joint Venture Transaction with Dragon Overseas Capital Limited
GuruFocusNews
•
9:00am
Apr 04, 2022
Oncotelic and Dragon Overseas Capital Limited Completed Joint Venture Transaction
GuruFocusNews
•
6:00am
Feb 24, 2022
Oncotelic Presenting at MedInvest Pharmaceutical and Biotechnology Investor Conference
GuruFocusNews
•
8:00am
Jan 19, 2022
Oncotelic Presenting at BiotechGate Digital Partnering
GuruFocusNews
•
9:00am
Dec 22, 2021
ONCOTELIC ANNOUNCES THAT ORF8 MUTATIONS ARE DRIVING THE EVOLUTION OF THE DELTA AND THE OMICRON VARIANTS.
GuruFocusNews
•
7:00am
Dec 14, 2021
Oncotelic's Dr. Anthony Maida to Present at 2nd Annual TGF-? for Immuno-Oncology Drug Development Summit in January 2022
GuruFocusNews
•
9:00am
Dec 01, 2021
Oncotelic Initiates Phase 2 Trial Evaluating OT-101 in Combination with KEYTRUDA® for Mesothelioma
GuruFocusNews
•
9:00am
Nov 23, 2021
ONCOTELIC PROVIDES 3RD QUARTER 2021 COMPARED TO 3RD QUARTER 2020 FINANCIAL RESULTS AND CORPORATE UPDATE
GuruFocusNews
•
7:00am
ONCOTELIC ANNOUNCES POSITIVE TOPLINE DATA FOR OT-101 C001 COVID STUDY
GuruFocusNews
•
6:00am
Apr 20, 2021
ONCOTELIC THERAPEUTICS, INC. ANNOUNCES POSITIVE TOP LINE DATA FOR ARTI-19 CLINICAL TRIAL EVALUATING PULMOHEAL™ VERSUS COVID-19.
Marketwired
•
11:00am
Apr 19, 2021
ONCOTELIC THERAPEUTICS, INC. ANNOUNCED SYNERGY BETWEEN OT-101 AND IL-2 (PROLEUKIN) AT AACR-2021
Marketwired
•
11:00am
Total 126
1
2
3
4
Show
20
40
60
80
100
No data
Entries
Headlines
Total 0
1
No recent news